BothCases
Example report. Sign up to run the same analysis on any ticker.
CRWV logoCRWVEquity research

Report date: 2026-11-11

$39.72-5.19 (-11.56%)Live · delayed quote, informational only

Analysis focus

Provide a balanced, comprehensive analysis: fundamentals and valuation, the Wall Street view, technical posture, and the key forward risks and catalysts.

Summary

CoreWeave's Q3 2026 print shows very fast demand growth set against a heavy financing burden. Revenue was $3.66B, up 168% year over year. That beat the LSEG consensus of about $3.55B [1] (another source puts consensus at $3.54B [11]) and topped the company's own $3.4B–$3.6B guide [21]. Backlog rose to $132.5B from about $104B in June [1][14]. Management raised FY26 revenue guidance to $13.0–13.3B from $12.4–13.2B, and adjusted operating income guidance to $1.275–1.375B from $0.96–1.15B, against a $1.07B consensus. It guided Q4 revenue to $4.7–5.0B and targets a $20–21B annualized run-rate by year-end [2]. The financing side is the other half of the picture. Q3 interest expense was $846M, up from $310M a year earlier and about 23% of revenue. That is slightly below the $860M–$940M guide [17][21], but far above GAAP operating income of $207M, a 6% margin. Q4 interest is guided higher still, to $1.05–1.15B [3]. Total debt is about $47B, Q3 free cash flow was roughly -$7.7B, FY26 capex is targeted at $37–39B and the current ratio is below 0.5 [4]. Some bonds have yielded above 15–16% [4], and the 9.625% 2032 notes fell below 80 cents on the dollar on Oct 14 [14][17]. Management says it will not issue unsecured parent-level debt at current yields and will fund most remaining capex through delayed-draw term loans tied to customer contracts [4][18]. Depreciation plus interest took about 79% of Q2 revenue [18]. The consensus 2027 loss estimate has widened to $4.68 per share from $3.69 [20]. No one-time items in the Q3 results could be identified or normalized from the verified findings [21]. The case for selling or staying away rests on that financing gap. The company pays interest of nearly $4 for every $1 of operating profit at Q3 guidance midpoints [18], cash burn is deeply negative, credit markets are signalling stress, and estimated losses keep widening [3][4][14][20]. Standard multiples don't help: trailing P/E is negative at about -13x, there is no dividend, and there is no 5-year valuation history because the stock listed in March 2025 [12]. At $48.73 the market cap is about $25.6–27.0B. Adding about $47B of debt gives a gross enterprise value near $74B before cash, so equity holders sit behind a large debt stack [8]. The case for holding rests on growth and price. Forward price-to-sales is about 1.4x, the lowest in a year, while Citi's $128 target implies about 3.6x, roughly the one-year average [20]. The guidance raise and backlog suggest the slide into November reflected financing stress and macro or customer worries rather than weaker demand [1][2][17]. Those worries include Microsoft capex of $45.2B against $50.7B expected and a data-center selloff after the midterms [17][21]. A peer comparison is weak: for Nebius only analyst targets of about $240–295 were found, with no comparable fundamentals [5][20]. The Street is still positive but losing conviction. Of 42 analysts, 25 rate the stock Strong Buy, 7 Buy, 7 Hold, 1 Sell and 2 Strong Sell [6]. The average target is $131.53 and the median $126.50, implying roughly 160–170% upside, with a range of $39–$278 [7]. TIKR puts the mean near $135, down from $142 a year earlier [22]. Targets have come down sharply even where ratings stayed positive: Citi to $128 from $159, Wells Fargo to $115 from $160, Raymond James to $75 from $125 and Rosenblatt to $160 from $250. Barclays held Equal Weight at $105, and HSBC rates the stock Reduce with a $39 target [5][13][19]. JPMorgan's September upgrade and UBS's Buy initiation are only weakly confirmed [23]. The gap between targets and the price suggests many targets have not caught up with the roughly 65% fall from the May high [7][17]. On the chart, the stock is about 54% lower over 12 months and 57% lower over 6 months [9], and trades near the bottom of its $40.58–$138.25 52-week range [8][16]. Price sits almost exactly on the 50-day SMA ($48.72), just under the 50-day EMA ($49.58), and about 25% below the 200-day SMA ($64.75), so the longer-term trend is bearish [10]. RSI(14) recovered to a neutral 52.4 from 33.66 in mid-October [15]. Support is at $46.1–47.0 and then $40.58, with resistance at about $49.6 and then $61.7–64.8 [16]. After hours the stock rose about 8–12%, to $52.58–$54.75 [11][21]. That would put it above the 50-day averages but still well below the 200-day band, and it is not a confirmed regular-session move. Near-term things to watch: - Q4 delivery against the $4.7–5.0B guide and the $20–21B run-rate target [2]. - Whether the contract-backed term-loan financing gets done [18]. - How bond prices and yields move [4][14]. - Post-earnings target and rating revisions [6][22].

Findings (23)

CoreWeave reported Q3 2026 revenue of $3.66 billion, up 168% from about $1.36 billion a year earlier and above the LSEG consensus of $3.55 billion; revenue backlog rose to $132.5 billion from $104 billion as of June 2026.

High confidence

CNBC gives the $3.66B revenue against the $3.55B LSEG estimate, the year-ago $1.36B figure, and the $132.5B backlog versus $104B in June. The Motley Fool reports the same revenue and backlog, and the company's Q3 2026 earnings presentation is the primary source.

FY2026 guidance was raised to $13.0–13.3 billion of revenue (from $12.4–13.2 billion) and $1.275–1.375 billion of adjusted operating income (from $0.96–1.15 billion, against a $1.07 billion consensus); Q4 revenue is guided to $4.7–5.0 billion, with an annualized run-rate of $20–21 billion targeted by the end of 2026.

High confidence

CNBC gives the old and new revenue and adjusted operating income ranges along with the consensus figures. The Motley Fool gives the Q4 revenue guide, and the Benzinga earnings-call transcript is the source for the run-rate target.

Interest expense was $846 million in Q3 2026, versus $310 million a year earlier and about 23% of quarterly revenue, and Q4 2026 interest expense is guided to $1.05–1.15 billion; this far exceeds GAAP operating income of $207 million (a 6% margin).

High confidence

The Motley Fool lists the $846M interest expense against $310M a year earlier, the $207M GAAP operating income at a 6% margin, and the $1.05–1.15B Q4 interest guidance. The 23% ratio is $846M divided by $3.66B of revenue.

Total debt was about $47 billion at the end of Q3 2026 and free cash flow was roughly -$7.7 billion for the quarter; full-year 2026 capex is targeted at $37–39 billion, some CoreWeave bonds have recently yielded more than 15–16%, and the current ratio is below 0.5.

High confidence

CNBC reports the roughly $47B of debt, the $37–39B capex target and bond yields above 16%, and says management plans no new parent-level unsecured debt through 2027 at current yields. The Motley Fool gives the -$7.7B quarterly free cash flow and the current ratio below 0.5.

The sell-side consensus is still positive, with an average price target of about $131 across roughly 42 analysts (range $39 to $278), but targets were cut heavily in November 2026: Citi to $128 from $159, Wells Fargo to $115 from $160, Raymond James to $75 from $125, and HSBC sits at Reduce with a $39 target; peer Nebius (NBIS) has average targets of about $240–295.

Medium confidence

Stockanalysis.com (S&P Global data) and Benzinga list the consensus figures and the individual cuts. Aggregators disagree on some cut dates, most target changes came before the Q3 print, and the Nebius figures come from aggregators with partly October data. No post-earnings revisions or comparable Nebius fundamentals were verified.

As of November 9, 2026, 42 analysts tracked by S&P Global gave CoreWeave (CRWV) a consensus 'Buy': 25 Strong Buy, 7 Buy, 7 Hold, 1 Sell and 2 Strong Sell.

High confidence

Stockanalysis.com gives the November 2026 rating breakdown as 25/7/7/1/2 across 42 analysts. TIKR separately counts 42 covering analysts but gives no breakdown. Both are secondary aggregators, and the counts are from before the November 10 Q3 report, so post-earnings revisions may change them.

The average 12-month price target is $131.53 and the median is $126.50, against a November 10, 2026 close of $48.73. That implies roughly 170% and 160% upside, and the target range runs from $39 (about 20% below the price) to $278.

High confidence

Stockanalysis.com lists an average of $131.53, a median of $126.50, a low of $39 and a high of $278. TIKR independently confirms the $39–$278 range and gives a roughly $135 average, down from $142 a year earlier. The upside figures are my own calculations from the $48.73 close. A target average this far above the price suggests many targets have not yet caught up with the stock's roughly 65% fall since May.

CRWV closed at $48.73 on Nov 10, 2026, near the bottom of its 52-week range of $40.58–$138.25, for a market cap of roughly $25.6–27.0 billion depending on the share count used; adding about $47 billion of debt gives a gross enterprise value near $74 billion before cash.

Medium confidence

The Motley Fool shows the $48.73 close, the 52-week range and a $27.01B market cap, but notes that figure counts publicly traded shares only. Aggregators show $25.6–27.0B. No source reported cash or enterprise value directly, so the EV is my calculation (market cap plus debt) and is overstated by whatever cash the company holds.

CRWV closed at $48.73 on 2026-11-10. That is about 57% below its ~$114.15 close around 2026-05-11, putting the 6-month return near -57%, and about 54% below its $105.61 close on 2025-11-10, putting the 12-month return near -54%.

Medium confidence

The $48.73 close comes from stockanalysis.com's price history. Cryptonomist reported a daily close of $114.15 around May 11, 2026, and TIKR cited a $105.61 close for Monday, Nov 10, 2025. The returns are calculated from those three closes, and the May reference comes from a lower-quality technicals site.

As of the 2026-11-10 close, CRWV ($48.73) sat almost exactly on its 50-day SMA ($48.72), just under its 50-day EMA ($49.58), and about 25% below its 200-day SMA ($64.75), with the 200-day EMA at $61.65. That leaves the longer-term trend bearish, even though price is testing the shorter-term average.

High confidence

Investing.com's technical page, timestamped Nov 10, 2026, shows MA50 simple 48.72, MA50 exponential 49.58, MA200 simple 64.75 and MA200 exponential 61.65 against a $48.73 close. The page also gives conflicting summary signals: 'Buy' in the headline and 'Strong Sell' for the daily timeframe.

Q3 2026 results reported on 2026-11-10 beat consensus: revenue of $3.66B against ~$3.54B expected, up ~168% year over year. Backlog was ~$132.5B at Sep 30, and FY26 revenue guidance was raised to $13.0B–$13.3B from $12.4B–$13.2B. Shares rose about 8–12% after hours ($52.58–$54.75) from the $48.73 close.

Medium confidence

Stockanalysis.com's news feed carries TheFly's figures on revenue, backlog, guidance, FY26 capex of $37B–$39B and the $20B–$21B exit run-rate. The prior $12.4B–$13.2B guidance comes from TIKR. The after-hours prints were $52.58 on stockanalysis.com and $54.75 on investing.com. These figures have not yet been checked against the primary 8-K, and the size of the after-hours move is not a confirmed regular-session reaction.

Standard earnings multiples are not meaningful for CRWV: trailing P/E is negative at about -13x because of GAAP losses, P/B is about 5.4x and P/S about 7.2x per an aggregator, the stock pays no dividend, and there is no 5-year valuation history because CoreWeave listed in March 2025.

Medium confidence

The aggregator lists P/E of -13.24x, P/B of 5.38x and P/S of 7.23x. Macrotrends price history starts in 2025, so only about 20 months of trading history exists. No source verified a dividend or EV/EBITDA, which is why the confidence is medium.

Major-bank targets compared with the $48.73 close: Citi Buy at $128 (cut from $159, about +163%), Wells Fargo Buy at $115 (cut from $160, about +136%), and Barclays Equal Weight/Hold at $105 (kept on October 27, 2026, about +115%).

Medium confidence

Stockanalysis.com lists the Citi (Tyler Radke), Wells Fargo (Michael Turrin) and Barclays (Raimo Lenschow) actions with their old and new targets. TIKR dates Citi's $159→$128 cut to November 4, while stockanalysis.com logs it on November 9, so the exact date is uncertain. I found no current, verified 2026 targets from Morgan Stanley or BofA.

Backlog was $104.2B at June 30, 2026, plus more than $25B of new commitments signed early in Q3, but Q2 interest expense rose to $640M from $267M a year earlier, against adjusted operating income of only $128M. CoreWeave's 9.625% notes due 2032 fell below 80 cents on the dollar on October 14, 2026.

Medium confidence

Pulse2 and TIKR both report the roughly $104B backlog plus more than $25B of new Q3 commitments. TIKR provides the interest-expense, adjusted operating income and bond-price figures, and says depreciation plus interest took about 79% of Q2 revenue. Both are secondary sources; I did not verify these numbers against the 10-Q. Strong demand alongside heavy financing costs and falling credit prices is the core tension behind the target cuts.

RSI(14) read 52.4 (neutral) at the 2026-11-10 close, up from 33.66, near oversold, in an October 17, 2026 snapshot. That suggests downside momentum had eased into the Q3 print, but the stock was neither overbought nor oversold.

Medium confidence

Investing.com listed RSI(14) at 52.406 'Neutral' for Nov 10, 2026. An earlier investing.com snapshot dated Oct 17, 2026 showed RSI(14) at 33.663 with stochastic in oversold territory. Both are aggregator snapshots, not computed from primary data.

The nearest support is the 52-week low of $40.58, with near-term pivot support at about $46.1–$47.0. Overhead resistance runs from the ~$49.6 50-day EMA to the ~$61.7–$64.8 band of 200-day averages, and the 52-week high was $138.25.

Medium confidence

Stockanalysis.com lists the 52-week range as $40.58–$138.25. Investing.com's classic pivots show S1 46.99, S2 46.69 and S3 46.13, and its moving-average table places the 200-day SMA and EMA at $64.75 and $61.65. Treat these as indicative levels, not hard floors or ceilings.

The slide into November was driven by rising financing stress and macro or customer worries rather than demand. Q2 interest expense rose to $640M from $267M a year earlier, the 9.625% 2032 notes fell below 80 cents on the dollar on Oct 14, Microsoft's $45.2B Q3 capex came in under the $50.7B expected, and data-center stocks sold off after the midterms. On Nov 4 the shares fell 9.9% to $48.42, about 65% below the May high.

Medium confidence

TIKR lists each of these drivers with figures, including Q3 interest guidance of $860M–$940M against $200M–$260M of adjusted operating income guidance. Stockanalysis.com confirms the $48.42 close on Nov 4, 2026. The interest figures come from company filings but are reported here second-hand.

Management said it will not issue unsecured debt at current yields and expects to fund most remaining FY26 capex ($37B–$39B guided) through delayed-draw term loans tied to specific customer contracts. This is a key forward risk and catalyst given that depreciation and interest consumed 79% of Q2 revenue.

Medium confidence

The financing statement and capex guidance appear in TheFly's Q3 coverage on stockanalysis.com. TIKR computes the 79% depreciation-plus-interest share of Q2 revenue and notes interest of nearly $4 for every $1 of operating profit at Q3 guidance midpoints.

In the past three weeks several bullish firms cut their targets sharply while keeping Buy ratings: Raymond James from $125 to $75 (October 26), Rosenblatt from $250 to $160 (November 9) and Wells Fargo from $160 to $115 (November 9).

Medium confidence

Stockanalysis.com's recent-actions table shows all three cuts with the analyst names. Ratings stayed positive even as targets fell 31–40%, which suggests weaker conviction on valuation rather than a change of thesis. This comes from one secondary aggregator.

CRWV traded at about 1.4x forward price-to-sales in early November 2026, its lowest in a year, while Citi's $128 target implies about 3.6x, roughly the stock's one-year average. The consensus 2027 loss estimate has widened to $4.68 per share from $3.69 three months earlier.

Medium confidence

TIKR reports the 1.4x forward P/S, the 3.6x multiple implied by Citi's target, a 2027 revenue estimate of $26.5B and the wider $4.68 loss estimate. CoreWeave listed in 2025, so there is no five-year valuation history to compare against, and I did not verify a peer multiple (for example Oracle or Nebius) in this research.

CoreWeave reported Q3 2026 results on November 10, 2026. The stock rose to $52.58 after hours from a $48.73 close (about +7.9%), against company guidance of $3.4B–$3.6B in Q3 revenue and $860M–$940M in Q3 interest expense.

Low confidence

Stockanalysis.com shows the close and after-hours prices. SiliconANGLE (August 2026) gives the Q3 revenue guidance, and TIKR gives the interest guidance and the November 10 report date. I could not get the actual Q3 figures (the investor-relations page did not load), so any one-time items in the results are unverified. Other catalysts and risks cited include Microsoft's Q1 capex of $45.2B against $50.7B expected and possible limits on data-center construction after the midterms.

Wall Street remains constructive on price targets despite the drawdown. Across 42 analysts the mean 1-year target is about $135, down from $142 a year earlier, with a range of $39–$278. Citi cut its target to $128 from $159 on Nov 4 while keeping a Buy rating, and the stock trades near 1.4x forward sales, its lowest in the past year.

Medium confidence

TIKR reports the 42-analyst mean target, its range and the Citi action by analyst Tyler Radke, along with an NTM price/sales of about 1.4x and a 2027 consensus loss of $4.68 per share. CRWV listed in 2025, so a 5-year valuation history does not exist. These targets predate the Q3 print and may be revised.

In the 90-day window, JPMorgan upgraded CRWV from Neutral to Overweight on September 24, 2026, and UBS started coverage at Buy on September 23, 2026. Goldman Sachs' last confirmed stance is Neutral with an $86 target from January 2026, about 76% above today's price.

Low confidence

Search snippets of the Nasdaq article report the JPMorgan upgrade and the UBS initiation, but I could not load the article (it timed out), so neither the date nor JPMorgan's target is confirmed. The Goldman figure comes from an aggregator snippet, is older than 90 days and may have been replaced.

Sources (25)

Caveats

Time-sensitive: this reflects data as of 2026-11-10/11. Analyst ratings, price targets and technical readings were all captured before the November 10 Q3 report, and post-earnings revisions were not verified [6][7][22]. The after-hours move ($52.58–$54.75) is not a regular-session close [11][21]. Data quality and conflicts: - Q3 consensus is $3.55B in one source and $3.54B in another [1][11]. Bond yields are described as above 15–16% and as above 16% [4]. The date of Citi's cut is given as Nov 4 or Nov 9 [13]. The mean target is $131.53 or about $135 depending on the aggregator [7][22]. - The aggregator's trailing P/S of about 7.2x [12] doesn't sit easily with the roughly 1.4x forward P/S [20] and the $25.6–27.0B market cap [8]. It may use a different revenue base or be stale. - Market cap depends on the share count used. Enterprise value is a rough calculation that leaves out cash, so it is overstated [8]. - Microsoft's $45.2B capex quarter is labelled Q3 in one finding and Q1 (fiscal) in another [17][21]. - Several figures come from secondary sources only: Q2 interest, backlog and bond-price data were not checked against the 10-Q [14], and some Q3 details were not checked against the 8-K [11]. - The May 2026 reference price comes from a lower-quality technicals site [9]. Investing.com's summary technical signals contradict each other [10]. - The JPMorgan upgrade, UBS initiation and Goldman target are low-confidence, and the Goldman target is stale [23]. Gaps: - One-time items in Q3 were not identified, so earnings could not be normalized. - Cash balance, EV/EBITDA, adjusted operating income and net loss for Q3 were not covered. - No peer fundamentals were verified. Nebius targets are only partly current [5][20]. - No 5-year valuation history exists because the stock listed in March 2025 [12]. - No current Morgan Stanley or BofA targets were found [13]. - Not covered: customer concentration, share dilution and lockups, insider activity, short interest, and the terms and covenants of the delayed-draw term loans.

This report is for informational purposes only and is not investment advice. No buy / sell / hold recommendation is made or implied.

More research reports

Recent reports from the same pipeline. See all examples

Want this on your watchlist?

Add your own focus, pick a delivery speed, and get a source-verified report like this one.